EU/3/12/1032

Haemophilia B is an inherited bleeding disorder that is caused by the lack of a substance called factor IX. Factor IX is one of the proteins involved in the blood-coagulation (clotting) process. Patients with haemophilia B are more prone to bleeding than normal and have poor wound healing after injury or surgery. Bleeding can also happen within muscles or the spaces in the joints, such as the elbows, knees and ankles, which can lead to permanent injury if it happens repeatedly.

Haemophilia B is a debilitating disease that is lifelong and may be life-threatening because bleeding can also happen in the brain and spinal cord, the throat or the gut.

At the time of designation, haemophilia B affected approximately 0.14 in 10,000 people in the European Union (EU). This was equivalent to a total of around 7,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

* Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein.
At the time of designation, this represented a population of 509,000,000 (Eurostat 2012).

At the time of designation, medicines containing factor IX were authorised in the EU for the treatment of haemophilia B. These medicines were used to replace the missing factor-IX protein. However, not all patients with haemophilia B could benefit from these medicines because the immune system (the body's natural defences) can react against them by producing 'inhibitors' (antibodies) against factor IX. In these cases, other treatments needed to be used, such as other coagulation factors such as factor VIIa, either alone or as part of a combination treatment.

The sponsor has provided sufficient information to show that vatreptacog alfa (activated) might be of significant benefit for patients with haemophilia B because early studies indicate that it could be used in haemophilia B patients who have developed inhibitors against factor VIII, to better control the bleeding episodes than existing treatments. The medicine is also expected to be given for a shorter period of time than existing medicines, which is expected to improve compliance with treatment. These assumptions will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

Vatreptacog alfa (activated) is expected to work in the same way as human factor VIIa. In the body, factor VIIa is involved in blood clotting. It activates another factor called factor X, which starts the clotting process. By activating factor X, this medicine is expected to control the bleeding disorder in patients who have developed inhibitors to factor IX because it acts directly on factor X, independently of factor IX.

Vatreptacog alfa (activated) is made by a method known as 'recombinant DNA technology': it is made by a cell that has received the human gene (DNA) that makes it able to produce factor VIIa. The protein has also been modified: its sequence of amino acids (the building blocks of proteins) is slightly different from that of naturally occurring factor VIIa, which may result in it activating more factor X than existing medicines.

The effects of vatreptacog alfa (activated) have been evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials with vatreptacog alfa (activated) in patients with haemophilia B were ongoing.

At the time of submission, vatreptacog alfa (activated) was not authorised anywhere in the EU for haemophilia B or designated as an orphan medicinal product elsewhere for this condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 11 July 2012 recommending the granting of this designation.

• the seriousness of the condition;
• the existence of alternative methods of diagnosis, prevention or treatment;
• either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.